ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
4
views
0
references
Top references
cited by
0
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,228
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
PCN145 COST EFFECTIVENESS OF FRUQUINTINIB VERSUS REGORAFENIB AS THE THIRD-LINE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER IN CHINA
Author(s):
G. Xin
,
H.C. Li
,
C. Peng
,
N. Wang
,
X. Ma
,
X.M. Xiong
,
A.X. Ma
Publication date
Created:
May 2019
Publication date
(Print):
May 2019
Journal:
Value in Health
Publisher:
Elsevier BV
Read this article at
ScienceOpen
Publisher
Further versions
open (via crossref license)
Powered by
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Procedural speed in criminal law
Author and article information
Journal
Title:
Value in Health
Abbreviated Title:
Value in Health
Publisher:
Elsevier BV
ISSN (Print):
10983015
Publication date Created:
May 2019
Publication date (Print):
May 2019
Volume
: 22
Page
: S83
Article
DOI:
10.1016/j.jval.2019.04.269
SO-VID:
50462bd9-d7f3-4d0c-a764-5a038f8afef3
Copyright ©
© 2019
License:
https://www.elsevier.com/tdm/userlicense/1.0/
History
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
1,228
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial
Authors:
J Li
,
S Qin
,
RH Xu
…
Fruquintinib for refractory colorectal cancer in a pre-treated 82-year-old patient achieved a progression-free survival of 25 months: a case report
Authors:
Yi Wang
,
Jianjiong Li
,
Qiyang Xu
…
Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer
Authors:
See all similar